0001752724-22-057665.txt : 20220311
0001752724-22-057665.hdr.sgml : 20220311
20220311160340
ACCESSION NUMBER: 0001752724-22-057665
CONFORMED SUBMISSION TYPE: N-CEN
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20211231
FILED AS OF DATE: 20220311
DATE AS OF CHANGE: 20220311
EFFECTIVENESS DATE: 20220311
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: T. Rowe Price U.S. Equity Research Fund, Inc.
CENTRAL INDEX KEY: 0000931151
IRS NUMBER: 521905304
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: N-CEN
SEC ACT: 1940 Act
SEC FILE NUMBER: 811-07225
FILM NUMBER: 22733094
BUSINESS ADDRESS:
STREET 1: 100 EAST PRATT STREET
CITY: BALTIMORE
STATE: MD
ZIP: 21202
BUSINESS PHONE: 410-345-2000
MAIL ADDRESS:
STREET 1: 100 EAST PRATT STREET
CITY: BALTIMORE
STATE: MD
ZIP: 21202
FORMER COMPANY:
FORMER CONFORMED NAME: T. Rowe Price Capital Opportunity Fund, Inc.
DATE OF NAME CHANGE: 20190523
FORMER COMPANY:
FORMER CONFORMED NAME: T. Rowe Price U.S. Equity Research Fund, Inc.
DATE OF NAME CHANGE: 20190523
FORMER COMPANY:
FORMER CONFORMED NAME: T. Rowe Price Capital Opportunity Fund, Inc.
DATE OF NAME CHANGE: 20051018
0000931151
S000002071
T. Rowe Price U.S. Equity Research Fund
C000005429
T. Rowe Price U.S. Equity Research Fund
PRCOX
C000005430
T. Rowe Price U.S. Equity Research Fund-Advisor Class
PACOX
C000005431
T. Rowe Price U.S. Equity Research Fund-R Class
RRCOX
C000177207
T. Rowe Price U.S. Equity Research Fund-I Class
PCCOX
C000232530
T. Rowe Price U.S. Equity Research Fund-Z Class
PCUZX
N-CEN
1
primary_doc.xml
X0404
N-CEN
LIVE
0000931151
XXXXXXXX
811-07225
false
false
false
N-1A
true
T. Rowe Price U.S. Equity Research Fund, Inc.
811-07225
0000931151
549300D7IR8KMVOUZX05
100 East Pratt Street
Baltimore
21202
US-MD
US
410-345-2000
State Street Corporation
1776 Heritage Drive
Quincy
02171
617-786-3000
Custodian records for the Registrant.
T. Rowe Price U.S. Equity Research Fund, Inc.
100 East Pratt Street
Baltimore
21202
410-345-2000
All accounts, books, and other documents required to be maintained by the Registrant under Section 31(a) of the Investment Company Act of 1940 and the rules thereunder.
JPMorgan Chase Bank, London
Woolgate House, Coleman Street
London
GB
EC2P 2HD
0 44 20 7742 4000
Records related to the custody of Registrant's portfolio securities which are purchased outside the United States.
The Bank of New York Mellon
103 Bellevue Parkway
Wilmington
19809
800-441-9800
Fund accounting records
T. Rowe Price Services, Inc.
100 East Pratt Street
Baltimore
21202
410-345-2000
Transfer, dividend disbursing, and shareholder service records
N
N
N-1A
1
Y
Bruce W. Duncan
N/A
N
Teresa Bryce Bazemore
N/A
N
John G. Schreiber
N/A
N
Robert W. Sharps
N/A
Y
Paul F. McBride
N/A
N
Kellye L. Walker
N/A
N
Robert J. Gerrard, Jr.
N/A
N
Ronald J. Daniels
N/A
N
David Oestreicher
004594569
Y
John R. Gilner
001909214
100 East Pratt Street
Baltimore
21202
XXXXXX
N
N
N
N
N
N
T. Rowe Price Investment Services, Inc.
008-25130
000008348
N/A
Y
N
PricewaterhouseCoopers LLP
238
5493002GVO7EO8RNNS37
N
N
N
N
N
N
N
T. Rowe Price U.S. Equity Research Fund
S000002071
F3LBM5TMT300W38DI523
N
5
1
0
N/A
N
N
Y
N
State Street Bank and Trust Company
571474TGEMMWANRLN572
N
N
N/A
N/A
N/A
Rule 32a-4 (17 CFR 270.32a-4)
Rule 12d1-1 (17 CFR 270.12d1-1)
Y
Y
N
N
T. Rowe Price Associates, Inc.
801-00856
000105496
7HTL8AEQSEDX602FBU63
N
T. Rowe Price Retirement Plan Services, Inc.
084-01917
N/A
Y
Y
T. Rowe Price Services, Inc.
084-01079
N/A
Y
N
N
Refinitiv US Holdings Inc.
549300NF240HXJO7N016
N
ICE Data Services
13-3668779
Tax ID
N
Bloomberg Finance L.P.
5493001KJTIIGC8Y1R12
N
Markit North America, Inc.
N/A
N
N
Skandinaviska Enskilda Banken AB, Oslo Branch
F3JS33DEI6XQ4ZBPTN86
NO
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
UBS Switzerland AG
549300WOIFUSNYH0FL22
CH
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
EUROCLEAR BANK SA/NV
549300OZ46BRLZ8Y6F65
BE
N
Y
Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7)
JPMorgan Chase Bank, N.A.
7H6GLXDRUGQFU57RNE97
N
Y
Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1))
State Street Bank and Trust Company
571474TGEMMWANRLN572
N
N
Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1))
JPMorgan Chase Bank, N.A. - Sydney Branch
7H6GLXDRUGQFU57RNE97
AU
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
BNP Paribas Securities Services S.C.A. - Milan Branch
549300WCGB70D06XZS54
IT
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
J.P. Morgan Bank Luxembourg S.A.
7W1GMC6J4KGLBBUSYP52
LU
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
Royal Bank of Canada
ES7IP3U3RHIGC71XBU11
CA
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
Mizuho Bank, Ltd.
RB0PEZSDGCO3JS6CEU02
JP
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
JPMorgan Chase Bank, London
7H6GLXDRUGQFU57RNE97
GB
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
N
T. Rowe Price Retirement Plan Services, Inc.
N/A
Y
Y
T. Rowe Price Services, Inc.
N/A
Y
N
N
T. Rowe Price Associates, Inc.
7HTL8AEQSEDX602FBU63
Y
N
N
T. Rowe Price Investment Services, Inc.
008-25130
000008348
N/A
0.00000000
JP MORGAN CHASE & CO.
N/A
N/A
8I5DZWZKVSZI1NUHU748
86220.00000000
Bank of America Corporation
N/A
N/A
9DJT3UXIJIZJI4WXO774
41362.00000000
Citigroup, Inc.
N/A
N/A
6SHGI4ZSSLCXXQSBB395
69868.00000000
Royal Bank of Canada
N/A
N/A
ES7IP3U3RHIGC71XBU11
CA
41101.00000000
UBS Group AG
N/A
N/A
549300SZJ9VS8SGXAN81
CH
54624.00000000
BMO Capital Markets Corp.
N/A
N/A
NQQ6HPCNCCU6TUTQYE16
CA
32430.00000000
The Goldman Sachs Group, Inc.
N/A
N/A
784F5XWPLTWKTBV3E584
56755.00000000
Morgan Stanley
N/A
N/A
IGJSJL3JD5P30I6NJZ34
68408.00000000
SANFORD C. BERNSTEIN & CO., LLC
N/A
N/A
N/A
71817.00000000
BARCLAYS PLC
N/A
N/A
213800LBQA1Y9L22JB70
GB
46121.00000000
825642.00000000
Citigroup Inc.
N/A
N/A
6SHGI4ZSSLCXXQSBB395
3910193.00000000
Wells Fargo & Company
N/A
N/A
PBLD0EJDB5FWOLXP3B76
827263.00000000
The Goldman Sachs Group, Inc.
N/A
N/A
784F5XWPLTWKTBV3E584
14254990.00000000
Deutsche Bank Aktiengesellschaft
N/A
N/A
7LTWFZYICNSX8D621K86
DE
1796175.00000000
BARCLAYS PLC
N/A
N/A
213800LBQA1Y9L22JB70
GB
1842837.00000000
Bank of America Corporation
N/A
N/A
9DJT3UXIJIZJI4WXO774
4727352.00000000
Mizuho Financial Group, Inc.
N/A
N/A
353800CI5L6DDAN5XZ33
JP
734261.00000000
JP MORGAN CHASE & CO.
N/A
N/A
8I5DZWZKVSZI1NUHU748
11151473.00000000
Allen & Company LLC
008-12123
000001042
549300RO3RYDN328JY68
1595215.00000000
Morgan Stanley
N/A
N/A
IGJSJL3JD5P30I6NJZ34
9173772.00000000
54881230.00000000
Y
7503622759.00000000
0.00000000
N
N
N
false
false
true
false
false
false
INTERNAL CONTROL RPT
2
g.1.a.iii_trp_usequityres.htm
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of T. Rowe Price U.S. Equity Research Fund, Inc.
In planning and performing our audit of the financial statements of T. Rowe Price U.S. Equity Research Fund, Inc. (the “Fund”) as of and for the year ended December 31, 2021, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund’s internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund’s internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Fund’s internal control over financial reporting.
The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be material weaknesses as defined above as of December 31, 2021.
This report is intended solely for the information and use of the Board of Directors of T. Rowe Price U.S. Equity Research Fund, Inc. and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
February 15, 2022
PricewaterhouseCoopers LLP,100 East Pratt, Street, Suite 2600, Baltimore, Maryland 21202-1096T:4107837600, www.pwc.com/us